1. Thillai, M, Atkins, CP, Crawshaw, A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax 2021; 76: 4–20.
Google Scholar | Crossref | Medline2. Wijsenbeek, MS, Culver, DA. Treatment of sarcoidosis. Clin Chest Med 2015; 36: 751–767.
Google Scholar | Crossref | Medline3. Rahaghi, FF, Baughman, RP, Saketkoo, LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev 2020; 29: 190146.
Google Scholar | Crossref | Medline4. Judson, MA, Chaudhry, H, Louis, A, et al. The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 2015; 109: 526–531.
Google Scholar | Crossref | Medline | ISI5. Khan, NA, Donatelli, CV, Tonelli, AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017; 132: 9–14.
Google Scholar | Crossref | Medline6. Broos, CE, Wapenaar, M, Looman, CWN, et al. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. Eur Respir J 2018; 51: 1702089.
Google Scholar | Crossref | Medline7. Cremers, JP, Drent, M, Bast, A, et al. Multinational evidence-based world association of sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19: 545–561.
Google Scholar | Crossref | Medline8. Kahlmann, V, Janssen Bonas, M, Janssen Bonás, M, et al. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med 2020; 20: 271.
Google Scholar | Crossref | Medline